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Abstract
Introduction: The health-related quality-of-life (HRQoL) instruments are an important tool for the evaluation of
medical outcomes. Sexually transmitted diseases (STDs) influence the patients’ life. We aimed to evaluate the
HRQoL in patients with anogenital warts at the time of and 1 month after the diagnosis.
Materials and methods: We used the short-form (SF)-36 questionnaire to compare the HRQoL of 91 patients with
anogenital warts to 53 control subjects with the same socioeconomic characteristics.
Results: There was no statistical difference in the overall HRQoL measurement between the anogenital wart
patients and controls. However, there was an improvement in the scales of vitality (65.22 ± 15.70 vs. 69.04 ± 14.11,
respectively; p < 0.05) and mental health (65.00 ± 20.09 vs. 69.43 ± 18.08, respectively; p < 0.05) in anogenital warts
patients between the time of diagnosis and 1 month later. Furthermore, there was a significant deterioration in the
scale of social functioning (73.47 ± 22.18 vs. 72.89 ± 19.28, respectively; p < 0.05). The small sample size is a
limitation of our study.
Conclusions: HRQoL does not appear to be influenced in anogenital wart patients, as measured by the generic
instrument SF-36. It is therefore important to develop specific instruments for the measurement of HRQoL in this
group of patients.
Introduction
Sexually transmitted diseases (STDs) are a group of dis-
eases that are transmitted through sexual intercourse
and are caused by a wide variety of pathogenic micro-
organisms. Until this day, more than 50 micro-organ-
isms have been recognised as a cause of STDs [1].
These diseases comprise a global challenge for health
care systems [2-4]. As STDs have reached epidemic
dimensions, they are recognized as a considerable threat
for public health. In addition, STDs are a cause of acute
illness, infertility, disability and death, with serious med-
ical and psychological consequences for millions of peo-
ple. The STD epidemic is associated with several
political, socioeconomic, behavioural, biochemical and
biomedical factors.
According to the World Health Organization and
Eurostat, there are 28 million new STD cases in Europe
per annum [3,4]. The highest incidence is observed in
urban populations between 15-35 years of age [3,4].
Skin diseases may have a considerable effect on the
patient’s quality-of-life (QoL). In 20-50% of patients
with skin diseases in secondary care, the decrease in the
QoL may be severe enough to classify the patient at risk
of developing severe psychosocial impairment or psy-
chiatric morbidity such as clinical depression [5-7].
Human papillomavirus (HPV) infection is the most
common cause of STDs worldwide with 50% of the
cases involving individuals aged 15-25 years [8,9]. More
than 100 different types of HPV have been identified
[ 1 0 ] ,3 0o r4 0o fw h i c hc a ni n f e c tt h em u c o s aa n ds k i n
of the anogenital area [11,12]. Clinically, anogenital
warts consist of epidermal and dermal papules or
nodules on the perineum, genitalia, crural folds and
a n u s .T h e yv a r yi ns i z ea n dc a nf o r ml a r g e ,e x o p h y t i c
(cauliflower-like) masses, especially in the moist envir-
onment of the perineum. Discrete 1-to 3- mm sessile
warts may occur on the penile shaft. Warts may extend
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lium [1].
The health-related QoL (HRQoL) is very important
for the evaluation of medical outcomes. It is measured
with generic and disease-specific instruments. These
instruments are more important in fields such as Der-
matology where mortality is a relatively rare outcome.
There is only 1 specific instrument of measuring
HRQoL in patients with anogenital warts [13], which
has neither been properly adjusted, nor has it been
widely translated to be clinically applied.
In the present study we aimed to evaluate the HRQoL
in patients with anogenital warts at the time of diagnosis
and at one-month follow-up using the generic instru-
ment short-form (SF)-36 [14,15].
Materials and methods
Between March and October 2008, a total of 240
patients diagnosed for the first time with anogenital
warts in the Sexually Transmitted Infections Unit of the
“Andreas Sygros” Hospital for Skin and Venereal Dis-
eases were asked to participate in the study. The study
consisted of completing the SF-36 questionnaire both at
the time of the diagnosis (t0)a n d1m o n t hl a t e r( t 1). A
total of 53 healthy individuals who visited the hospital
for acquiring a health certificate comprised the control
group. The study participants comprising the control
group filled in the questionnaire only once.
The SF-36 is a generic, self-administered, multi-item
questionnaire measuring HRQoL, which is widely used
in health services research. It consists of 8 scales: Physi-
cal Functioning (PF), Role limitations due to Physical
problems (RP), Bodily Pain (BP), General Health (GH),
Vitality (V), Social Functioning (SF), Role limitations
due to Emotional problems (RE) and Mental Health
(MH) [16-18]. Each scale ranges between 0 (worst
health) and 100 (best health). Furthermore, we com-
pared these results with the scores of SF-36 in patients
w i t ho t h e rd i s e a s e sa sw e l la si nt h eg e n e r a lG r e e k
population, where this questionnaire has already been
adapted and evaluated [19-21].
This Ethical Committee of the Athens Hospital for
Skin Diseases “Andreas Sygros” approved of the study.
A written informed consent was obtained from all
patients at the time of study entry.
The SF-36 scales were scored according to the docu-
mented procedures [16]. Higher scores indicate a better
HRQoL. All the statistical analyses were performed with
STATA S/E 9.2. A p-value < 0.05 was considered as
showing significant results.
Results
A total of 91 patients completed the study. The drop-
outs and response rates are presented in Figure 1.
The sociodemographic characteristics of the study par-
ticipants are presented in Table 1. The results of the 8
scales of SF-36 between the two time intervals in
patients with anogenital warts and in the control group
are presented in Table 2. In this Table, the scores of the
8 scales for the general population in Greece were also
included.
There was no difference in the scores of SF-36
between the patient and the control groups. In 5 of the
8 scales (PF, BP, GH, RP and RE) there was also no sig-
nificant difference in the 2 consecutive measurements of
the patient group. In contrast, there was a slight but sig-
nificant improvement in V and MH in the patient group
between the 2 time intervals. Furthermore, there was a
slight but significant deterioration in SF in the patient
group between the 2 time intervals.
Discussion
Our study showed that patients with anogenital warts
show an improvement in vitality and mental health 1
month after the establishment of the diagnosis. The pos-
sible reasons for this improvement may be the clinical
improvement or the clearing of the lesions after 1
month of treatment and the familiarity with the disease.
In contrast, our patients showed a slight but significant
Figure 1 Flow chart of patients during the study.
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result of feelings of guilt or shame for their condition
resulting to avoidance/restriction of social contacts.
According to the literature, patients with anogenital
warts suffer anxiety about the effect of the disease on
their sexual [13,22-27] and social relationships [13,23],
the stigma of having contracted a venereal disease
[25,27], the uncertain treatment success and time to
cure [13,22,23,26] and transmission of the disease to
others [13,22-25]. Several studies report that the
negative psychological effects of the disease are the most
difficult to treat [23,25,27]. They include feelings of
anger, fear caused by the relationship of HPV to cervical
cancer, guilt, depression, self-loathing and worries about
the future [13,22-29]. Finally, the literature points to an
increased need for more information about the disease
and an improved communication between physicians
and patients [22,23,25,27].
Μore male than female patients were recruited in our
study. This is because morem a l ep a t i e n t sw i t hS T D s
seek help for their condition in a hospital for Skin and
Venereal Diseases, like ours. Most women consult their
gynecologist for conditions like STDs. Furthermore, the
small number of women who attended our hospital did
not wish to participate in the study.
Our study has some limitations. Firstly, the sample
size was relatively small. Nevertheless, it was adequate
to reach significant conclusions. In addition, the popula-
tion of our study was patients attending a public, specia-
lized hospital; it did not include patients from general
hospitals, as well as patients from private practitioners.
It also did not include more wealthy patients who
usually prefer private hospitals to maintain their anon-
ymity, as well as those women who are treated by other
specialists (e.g. gynecologists). Therefore one should not
generalize the results in such groups if patients.
Based on the above-mentioned arguments, a credible
questionnaire/tool is required to measure psychological
burden on patients with anogenital warts. The develop-
m e n to fas p e c i f i cq u e s t i o n n a i r ef o rm e a s u r i n gH R Q o L
in patients with anogenital warts, as described by Badia
and associates [13], could demonstrate the degree of
psychological/social/physical burden of this condition to
patients. In addition, use of this questionnaire in differ-
ent populations (i.e. with different religions, ethical and
social beliefs, etc.) will help in drawing conclusions
about the relative burden of the condition according to
the patients’ background.
There are several clinical implications of our study.
Firstly, by use of the questionnaire, patients are directly
involved and may participate in their treatment more
actively. This way the emphasis is shifted from disease-
oriented to patient-oriented treatment. For this reason
assessment of the HRQoL has been routinely used as a
measure of efficacy in clinical practice and research [30].
Additionally, there is the potential for physicians to
receive feedback from the patients regarding the effec-
tiveness of the treatment and their degree of satisfaction.
Furthermore, the use of the SF-36 in specific patient
subgroups with different religious or cultural back-
ground compared to the rest of the Greek population (e.
g. Muslims, refugees, etc.) may have a different effect on
HRQoL. Finally, the employment of these tools will
enable the more objective verification of the success or
Table 1 Socio-demographic characteristics of the study
participants
Socio-demographic characteristics of the study participants
Patients
(n = 91)
Controls
(n = 53)
Age, Mean 26.4 26.3
[95% Confidence Interval] [25.0 - 27.9] [24.5 - 28.2]
Gender %
Male 73 74
Female 27 26
Age group %
<2 0 7.7 9.4
20-29 71.4 67.9
30-39 14.3 17.0
40-55 6.6 5.7
Marital status %
Married 89.01 88.68
Single 6.59 5.66
Divorced 3.30 5.66
Widowed 1.10 0
Education %
Primary 1.10 1.89
Secondary 47.25 33.97
University 38.46 49.05
MSc/PhD 8.79 13.20
No answer 4.40 1.89
Household income %
< 500€ 14.29 9.43
501€ - 1000€ 30.77 26.41
1001€ - 2000€ 23.08 33.96
2001€ - 3000€ 9.89 9.43
3001€ - 5000€ 8.79 16.99
< 5001€ 8.79 1.89
No answer 4.40 1.89
Working status %
Working 61.54 62.26
Not working (unemployed, student,
housewifery)
36.26 35.85
No answer 2.20 1.89
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cate the patient himself/herself in the management of
the condition.
Conclusions
In conclusion, we found that there was an improve-
ment in the scales of vitality and mental health and a
deterioration in the scale of social functioning in ano-
genital warts patients between the time of diagnosis
and initiation of treatment and one month later. The
small sample size however is a limitation of our study.
HRQoL does not appear to be influenced in anogenital
wart patients, as measured by the generic instrument
SF-36. It is important to develop specific instruments
for the measurement of HRQoL in this group of
patients.
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